Shanghai Fosun Pharmaceutical (02196): The drug registration application for Sodium Chloride Injection has been accepted by the National Medical Products Administration.

Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its application for the registration of heparin sodium injection accepted by the National Medical Products Administration. This drug, developed independently by the group, is intended for the prevention and treatment of venous thrombosis and pulmonary embolism, prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major abdominal or thoracic surgery or at risk of thromboembolic diseases due to other reasons, treatment of atrial fibrillation with embolism, treatment of acute and chronic consumptive coagulopathy (disseminated intravascular coagulation), prevention of coagulation during arterial and cardiac surgery, prevention and treatment of peripheral arterial embolism, and use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis. As of October 2025, Suzhou Erye has accumulated approximately RMB 8.61 million (unaudited) in research and development investment for this drug. According to the latest data from IQVIA CHPA, the sales of heparin sodium injection in China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 1.386 billion in 2024. Before this drug can be produced commercially, it still needs to obtain drug registration approval, among other things. The acceptance of the drug registration application will not have a significant impact on the group's current performance.